VCI Wealth Management LLC Buys 1,205 Shares of Becton, Dickinson and Company (NYSE:BDX)

VCI Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 20.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,004 shares of the medical instruments supplier's stock after buying an additional 1,205 shares during the period. VCI Wealth Management LLC's holdings in Becton, Dickinson and Company were worth $1,589,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. State Street Corp raised its stake in Becton, Dickinson and Company by 0.8% during the 3rd quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier's stock valued at $3,364,096,000 after purchasing an additional 106,616 shares during the period. Geode Capital Management LLC raised its position in shares of Becton, Dickinson and Company by 1.8% during the third quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier's stock valued at $1,510,050,000 after buying an additional 111,101 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Becton, Dickinson and Company by 9.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier's stock worth $1,293,635,000 after buying an additional 460,440 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Becton, Dickinson and Company by 79.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier's stock worth $720,089,000 after acquiring an additional 1,317,723 shares during the last quarter. Finally, Clearbridge Investments LLC grew its stake in Becton, Dickinson and Company by 3.1% during the second quarter. Clearbridge Investments LLC now owns 2,984,524 shares of the medical instruments supplier's stock valued at $697,513,000 after acquiring an additional 89,157 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 597 shares of the business's stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $236.51, for a total value of $141,196.47. Following the completion of the sale, the executive vice president now directly owns 5,544 shares of the company's stock, valued at $1,311,211.44. The trade was a 9.72 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Shan sold 500 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now directly owns 5,741 shares in the company, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Evercore ISI boosted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st. Citigroup raised Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and increased their price target for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Piper Sandler lifted their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research note on Tuesday. Finally, StockNews.com downgraded Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $283.00.

Becton, Dickinson and Company Trading Up 0.4 %

Shares of Becton, Dickinson and Company stock traded up $1.05 on Tuesday, reaching $249.75. The company had a trading volume of 1,741,418 shares, compared to its average volume of 1,983,307. The firm has a market cap of $72.43 billion, a price-to-earnings ratio of 42.05, a P/E/G ratio of 1.72 and a beta of 0.39. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The firm's 50-day moving average price is $228.56 and its two-hundred day moving average price is $233.31. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $250.91.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the firm earned $3.42 earnings per share. Becton, Dickinson and Company's quarterly revenue was up 6.9% compared to the same quarter last year. As a group, research analysts predict that Becton, Dickinson and Company will post 14.42 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 1.67%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.